Bioequivalence Study of Favipiravir From Flupirava 200 mg Tablet (European Egyptian Pharmaceutical Industries , Egypt) Versus Avigan 200 mg Tablets (Man. by Toyama Chemical Co., Ltd Japan)
Condition:   Healthy Interventions:   Drug: Flupirava;   Drug: Avigan Sponsors:   Genuine Research Center, Egypt;   European Egyptian Pharmaceutical Industries Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 20, 2020 Category: Research Source Type: clinical trials

Safety, Tolerability, and Pharmacokinetics of SAB-185 in Healthy Participants
Conditions:   COVID-19;   SARS-CoV2 Interventions:   Biological: SAB-185;   Other: Normal saline Sponsors:   SAb Biotherapeutics, Inc.;   Department of Health and Human Services;   Joint Program Executive Office (JPEO) Chemical, Biological, Radiological, and Nuclear Defense (CBRND) Enabling Biotechnologies (EB) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 13, 2020 Category: Research Source Type: clinical trials

Safety, Tolerability, and Pharmacokinetics of SAB-185 in Ambulatory Participants With COVID-19
Conditions:   COVID-19;   SARS-CoV2 Interventions:   Biological: SAB-185;   Other: Normal Saline Sponsors:   SAb Biotherapeutics, Inc.;   Biomedical Advanced Research and Development Authority;   Joint Program Executive Office (JPEO) Chemical, Biological, Radiological, and Nuclear Defense (CBRND) Enabling Biotechnologies (EB) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 13, 2020 Category: Research Source Type: clinical trials

Safety, Tolerability, and Pharmacokinetics of SAB-185 in Healthy Participants
Conditions:   COVID-19;   SARS-CoV2 Interventions:   Biological: SAB-185;   Other: Normal saline Sponsors:   SAb Biotherapeutics, Inc.;   Department of Health and Human Services;   Joint Program Executive Office (JPEO) Chemical, Biological, Radiological, and Nuclear Defense (CBRND) Enabling Biotechnologies (EB) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 13, 2020 Category: Research Source Type: clinical trials

Safety, Tolerability, and Pharmacokinetics of SAB-185 in Ambulatory Participants With COVID-19
Conditions:   COVID-19;   SARS-CoV2 Interventions:   Biological: SAB-185;   Other: Normal Saline Sponsors:   SAb Biotherapeutics, Inc.;   Biomedical Advanced Research and Development Authority;   Joint Program Executive Office (JPEO) Chemical, Biological, Radiological, and Nuclear Defense (CBRND) Enabling Biotechnologies (EB) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 13, 2020 Category: Research Source Type: clinical trials

Safety, Tolerability, and Pharmacokinetics of SAB-185 in Healthy Participants
Conditions:   COVID-19;   SARS-CoV2 Interventions:   Biological: SAB-185;   Other: Normal saline Sponsors:   SAb Biotherapeutics, Inc.;   Department of Health and Human Services;   Joint Program Executive Office (JPEO) Chemical, Biological, Radiological, and Nuclear Defense (CBRND) Enabling Biotechnologies (EB) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 13, 2020 Category: Research Source Type: clinical trials

Safety, Tolerability, and Pharmacokinetics of SAB-185 in Ambulatory Participants With COVID-19
Conditions:   COVID-19;   SARS-CoV2 Interventions:   Biological: SAB-185;   Other: Normal Saline Sponsors:   SAb Biotherapeutics, Inc.;   Biomedical Advanced Research and Development Authority;   Joint Program Executive Office (JPEO) Chemical, Biological, Radiological, and Nuclear Defense (CBRND) Enabling Biotechnologies (EB) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 13, 2020 Category: Research Source Type: clinical trials

Safety, Tolerability, and Pharmacokinetics of SAB-185 in Healthy Participants
Conditions:   COVID-19;   SARS-CoV2 Interventions:   Biological: SAB-185;   Other: Normal saline Sponsors:   SAb Biotherapeutics, Inc.;   Department of Health and Human Services;   Joint Program Executive Office (JPEO) Chemical, Biological, Radiological, and Nuclear Defense (CBRND) Enabling Biotechnologies (EB) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 13, 2020 Category: Research Source Type: clinical trials

Safety, Tolerability, and Pharmacokinetics of SAB-185 in Ambulatory Participants With COVID-19
Conditions:   COVID-19;   SARS-CoV2 Interventions:   Biological: SAB-185;   Other: Normal Saline Sponsors:   SAb Biotherapeutics, Inc.;   Biomedical Advanced Research and Development Authority;   Joint Program Executive Office (JPEO) Chemical, Biological, Radiological, and Nuclear Defense (CBRND) Enabling Biotechnologies (EB) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 13, 2020 Category: Research Source Type: clinical trials

Safety, Tolerability, and Pharmacokinetics of SAB-185 in Healthy Participants
Conditions:   COVID-19;   SARS-CoV2 Interventions:   Biological: SAB-185;   Other: Normal saline Sponsors:   SAb Biotherapeutics, Inc.;   Department of Health and Human Services;   Joint Program Executive Office (JPEO) Chemical, Biological, Radiological, and Nuclear Defense (CBRND) Enabling Biotechnologies (EB) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 13, 2020 Category: Research Source Type: clinical trials

Safety, Tolerability, and Pharmacokinetics of SAB-185 in Ambulatory Participants With COVID-19
Conditions:   COVID-19;   SARS-CoV2 Interventions:   Biological: SAB-185;   Other: Normal Saline Sponsors:   SAb Biotherapeutics, Inc.;   Biomedical Advanced Research and Development Authority;   Joint Program Executive Office (JPEO) Chemical, Biological, Radiological, and Nuclear Defense (CBRND) Enabling Biotechnologies (EB) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 13, 2020 Category: Research Source Type: clinical trials

Safety, Tolerability, and Pharmacokinetics of SAB-185 in Healthy Participants
Conditions:   COVID-19;   SARS-CoV2 Interventions:   Biological: SAB-185;   Other: Normal saline Sponsors:   SAb Biotherapeutics, Inc.;   Department of Health and Human Services;   Joint Program Executive Office (JPEO) Chemical, Biological, Radiological, and Nuclear Defense (CBRND) Enabling Biotechnologies (EB) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 13, 2020 Category: Research Source Type: clinical trials

Safety, Tolerability, and Pharmacokinetics of SAB-185 in Ambulatory Participants With COVID-19
Conditions:   COVID-19;   SARS-CoV2 Interventions:   Biological: SAB-185;   Other: Normal Saline Sponsors:   SAb Biotherapeutics, Inc.;   Biomedical Advanced Research and Development Authority;   Joint Program Executive Office (JPEO) Chemical, Biological, Radiological, and Nuclear Defense (CBRND) Enabling Biotechnologies (EB) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 13, 2020 Category: Research Source Type: clinical trials

Safety, Tolerability, and Pharmacokinetics of SAB-185 in Healthy Participants
Conditions:   COVID-19;   SARS-CoV2 Interventions:   Biological: SAB-185;   Other: Normal saline Sponsors:   SAb Biotherapeutics, Inc.;   Department of Health and Human Services;   Joint Program Executive Office (JPEO) Chemical, Biological, Radiological, and Nuclear Defense (CBRND) Enabling Biotechnologies (EB) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 13, 2020 Category: Research Source Type: clinical trials

Effects of a novel nutraceutical combination (BruMeChol ™) in subjects with mild hypercholesterolemia: study protocol of a randomized, double-blind, controlled trial
DiscussionThis protocol study, planned to verify the effects of BruMeChol ™ dietary supplementation in subjects with mild hypercholesterolemia, could also contribute to new study designs for next large-scale multicenter clinical trials.Trial registrationAustralian New Zealand Clinical Trials Registry:ACTRN12619000170123. Retrospectively registered on 5 February 2019 (Source: Trials)
Source: Trials - July 6, 2020 Category: Research Source Type: clinical trials

Immune Status SARS-CoV-2 in a Sample of a Tertiary Eye Health Centre
Condition:   History of Covid-19, Seroprevalence Intervention:   Diagnostic Test: Antibody Test Sponsors:   University Hospital Tuebingen;   Institute of Clinical Chemistry and Pathobiochemistry, Department of Internal Medicine Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 24, 2020 Category: Research Source Type: clinical trials

MechanO-Chemical Ablation Versus CompreSSion
Conditions:   Varicose Veins;   Surgery Intervention:   Device: Endovenous Mechano- Chemical Ablation Sponsors:   Belarusian State Medical University;   Medical University of Warsaw Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 22, 2020 Category: Research Source Type: clinical trials